Suppr超能文献

药物特异性病史、皮肤试验和体外试验可减少β-内酰胺类药物超敏反应中药物激发试验的需求。

Drug-specific history, skin and in vitro tests can reduce the need for drug provocation tests in betalactam-hypersensitivity.

机构信息

Floridsdorf Allergy Center (FAZ), Vienna, Austria.

Floridsdorf Allergy Center (FAZ), Vienna, Austria.

出版信息

Allergol Int. 2021 Apr;70(2):244-251. doi: 10.1016/j.alit.2020.09.010. Epub 2020 Nov 13.

Abstract

BACKGROUND

Many patients report questionable drug hypersensitivity reactions (DHR) to betalactam antibiotics. A workup is required for objectivation. Direct drug provocation tests (DPTs) omitting a prior allergy workup are increasingly recommended as the primary diagnostic approach. However, apart from the risk of severe side effects, DPTs often are a scarce resource in overloaded healthcare-systems. We investigated how many cases can be solved by drug-specific history, drug-specific IgE, and skin tests obviating the need for DPT.

METHODS

We conducted a chart review in a retrospective cohort of 932 patients in an allergy outpatient centre from 2016 to 2017. Patients had been submitted to drug-specific history and specific IgE-, skin prick-, intradermal- and patch-tests with early and late readings with a series of penicillins and cephalosporins but DPTs were no option.

RESULTS

Overall, positive in vitro and/or skin tests were found in 96/932 (10.3%) patients. Drug-specific IgE was detected in 40/932 (4.3%) patients, 61/787 (7.8%) patients had positive skin tests. In vitro tests to Pencillin V showed the highest rate of positivity 24/479 (5.0%) and early readings of ampicillin the highest amongst the skin tests (3/49, 6.1%). Immediate skin tests were more often positive than delayed ones (75:45). The combination of all parameters including drug-specific history solved 346/932 (37.1%) cases while 586/932 (62.9%) remained unresolved. Self-reported DHR could be less often confirmed in females and young children (p < 0.05).

CONCLUSIONS

Testing with betalactams applying simple, cheap, and safe skin and blood tests can solve a third of DHR-cases on a high throughput scale.

摘要

背景

许多患者报告称对β-内酰胺类抗生素存在可疑的药物过敏反应(DHR)。需要进行检查以客观化。直接药物激发试验(DPT)在不进行过敏检查的情况下,作为主要诊断方法越来越受到推荐。然而,除了严重副作用的风险外,DPT 在负担过重的医疗保健系统中往往是一种稀缺资源。我们调查了通过药物特异性病史、药物特异性 IgE 和皮肤试验可以解决多少病例,从而避免了 DPT 的需要。

方法

我们对 2016 年至 2017 年在过敏门诊中心的 932 例患者进行了回顾性队列研究。这些患者接受了药物特异性病史以及针对一系列青霉素和头孢菌素的特异性 IgE、皮肤点刺、皮内和斑贴试验,且进行了早期和晚期读数。但 DPT 不是选择方案。

结果

总体而言,在 932 例患者中,96/932(10.3%)患者的体外和/或皮肤试验阳性。在 932 例患者中,40/932(4.3%)患者检测到药物特异性 IgE,61/787(7.8%)患者的皮肤试验阳性。青霉素 V 的体外试验阳性率最高,为 24/479(5.0%),氨苄青霉素的早期读数在皮肤试验中最高(3/49,6.1%)。即刻皮肤试验阳性率高于延迟皮肤试验(75:45)。包括药物特异性病史在内的所有参数的组合可解决 346/932(37.1%)例病例,而 586/932(62.9%)例病例仍未解决。在女性和年幼儿童中,自我报告的 DHR 较难得到证实(p<0.05)。

结论

采用简单、廉价且安全的皮肤和血液试验对β-内酰胺类药物进行检测,可以在高通量的情况下解决三分之一的 DHR 病例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验